Thor Medical starts commercial production at AlphaOne isotope facility

• Thor Medical started commercial production at its industrial-scale AlphaOne facility at Herøya Industrial Park.
• AlphaOne will produce lead-212, supported by thorium-228 and radium-224, targeting radiotherapeutics projected at USD 15 billion by 2030.
• First customer deliveries are expected in August 2026; capacity is set to ramp to 21,000 patient dose equivalents after three years.
• AlphaOne commissioning followed mechanical completion in April; the project was delivered on time and on budget.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thor Medical ASA published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.